Please assess the completion status of the following clinical trial:

Trial Title: Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-ST-segment elevation acute myocardial infarction.~* coronary angiography within 48 hours from admission.~* angiographic evidence of severe and diffuse coronary artery disease,not amenable to conventional direct revascularisation techniques by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI).~Exclusion Criteria:~* ST-segment elevation acute myocardial infarction,~* clinical history of heart failure~* left ventricular ejection fraction \<35%,~* any form of severe valvular dysfunction,~* previous implantation or indication to implant a cardioverter-defibrillator during the index admission,~* any increase in liver enzymes,~* history of any liver or muscle disease,~* renal failure with serum creatinine \>2.5 mg/dL (221 mmol/L),~* need for continued use of intravenous medications to relieve anginal symptoms,~* presence of any major comorbidity with life expectancy \<24 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full-dose atorovastatin (80 mg/d) (Type: EXPERIMENTAL): For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
- Conventional medical treatment (Type: NO_INTERVENTION): For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels \<100 mg/dL (2.5 mmol/L).

Based on this trial design, predict the completion outcome and termination type (if applicable).